ASX 200 reporting season: ResMed
ResMed capitalises on growth, Fisher & Paykel confronts tariff hurdles, and Credit Corp remains confident in US expansion despite challenges.
(AI video summary)
This video was created on 3 February for IG audiences by ausbiz.
Key financial results
ResMed (ASX:RMD)
- Revenue: $1.3 billion
- Revenue growth: 10% year-over-year (YoY)
- Operating profit: $417.2 million, a 52% increase
- Operating cash flow: $309 million
This growth is driven by strategic investments in technology and infrastructure, enhancing supply chain management and maintaining strong gross margins. ResMed is poised to capitalise on opportunities in consumer wearables for sleep health and GLP-1 weight loss drugs, as highlighted by managing director Mick Farrell.
Fisher & Paykel Healthcare (ASX:FPH)
- Revenue: $951 million
- Revenue growth: 18%YoY
- Net profit after tax: $153 million, a 43% increase
Fisher & Paykel Healthcare is dealing with tariffs on imports from Mexico, Canada, and China. The company manufactures 45% of its volume in Mexico and 55% in New Zealand, with 43% of its revenue from the United Statees (US). These tariffs could delay the company's goal of a 65% gross margin by two to three years. Fisher & Paykel plans to update its financial outlook in May.
Credit Corp Group (ASX:CCP)
- Revenue: $271.49 million
- Revenue growth: 45% YoY
- Net profit: $44.1 million
- Net profit growth: 464% YoY (compared to a $12.1 million net loss a year ago)
Credit Corp reported a 12% increase in US collections for the first half of 2025. Despite falling short of analyst expectations, the company is optimistic about securing additional purchases to meet its full-year guidance of a $150 million outlay in the US market. This suggests potential growth opportunities in the credit and debt collection sector.
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Discover how to trade the markets
Learn how indices work – and discover the wide range of markets you can spread bet on – with IG Academy's free ’introducing the financial markets’ course.
Put learning into action
Try out what you’ve learned in this index strategy article risk-free in your demo account.
Ready to trade indices?
Put the lessons in this article to use in a live account – upgrading is quick and easy.
- Get fixed spreads from 1 point on the FTSE 100
- Protect your capital with risk management tools
- Trade more 24-hour markets than any other provider
Inspired to trade?
Put your new knowledge into practice. Log in to your account now.
Live prices on most popular markets
- Forex
- Shares
- Indices
